martes, 26 de mayo de 2020

TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity | Journal of Experimental & Clinical Cancer Research | Full Text

TFEB-NF-κB inflammatory signaling axis: a novel therapeutic pathway of Dihydrotanshinone I in doxorubicin-induced cardiotoxicity | Journal of Experimental & Clinical Cancer Research | Full Text

Doxorubicin is effective in a variety of solid and hematological malignancies. Unfortunately, clinical application of doxorubicin is limited due to a cumulative dose-dependent cardiotoxicity. Dihydrotanshinone...
Authors:Xiaoping Wang, Qiyan Wang, Weili Li, Qian Zhang, Yanyan Jiang, Dongqing Guo, Xiaoqian Sun, Wenji Lu, Chun Li and Yong Wang
Citation:Journal of Experimental & Clinical Cancer Research 2020 39:93
Content type:Research
Published on: 

No hay comentarios:

Publicar un comentario